LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an­­d Serve as Models for Evaluating Cancer Therapeutics

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

(2016) Elizabeth C. Townsend et al.   CANCER CELL

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer

(2016) Akash Kumar et al.   NATURE MEDICINE

Organoid culture systems for prostate epithelial and cancer tissue

(2016) Jarno Drost et al.   Nature Protocols

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

(2016) Colin C. Pritchard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting

(2016) E S Antonarakis et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer

(2015) X. Zhang et al.   CLINICAL CANCER RESEARCH

Organoid development in cancer genome discovery

(2015) Dong Gao et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

The Evolving Role of Cytotoxic Chemotherapy in the Management of Patients with Metastatic Prostate Cancer

(2015) Elan Diamond et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

The genomic landscape of response to EGFR blockade in colorectal cancer

(2015) Andrea Bertotti et al.   NATURE

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

(2015) Hui Gao et al.   NATURE MEDICINE

DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma

(2015) Alice N. Weaver et al.   Oncotarget

Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer

(2014) Maria Thadani-Mulero et al.   CANCER RESEARCH

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

An androgen receptor N-terminal domain antagonist for treating prostate cancer

(2013) Jae-Kyung Myung et al.   JOURNAL OF CLINICAL INVESTIGATION

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling

(2013) Holly M. Nguyen et al.   PLoS One

Of mice and men-warning: Intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively

(2013) J.P. Michiel Sedelaar et al.   PROSTATE

The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men

(2012) S. Kopetz et al.   CLINICAL CANCER RESEARCH

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

(2012) Karim Fizazi et al.   LANCET ONCOLOGY

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

The complexity of prostate cancer: genomic alterations and heterogeneity

(2012) Lara K. Boyd et al.   Nature Reviews Urology

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants

(2011) Elahe A. Mostaghel et al.   CLINICAL CANCER RESEARCH

Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer

(2011) Gerhardt Attard et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases

(2011) Xiaotun Zhang et al.   PLoS One

Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers

(2011) A. Kumar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer

(2010) Bruce Montgomery et al.   BMC CANCER

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

(2010) Shihua Sun et al.   JOURNAL OF CLINICAL INVESTIGATION

Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven

(2009) G. Attard et al.   CANCER RESEARCH

Comparative Analyses of Chromosome Alterations in Soft-Tissue Metastases within and across Patients with Castration-Resistant Prostate Cancer

(2009) I. N. Holcomb et al.   CANCER RESEARCH

A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In vitro

(2009) V. C. Daniel et al.   CANCER RESEARCH

Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth

(2008) R. B. Montgomery et al.   CANCER RESEARCH

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY